Zai Lab LTD 10-Q quarterly reports

Zai Lab reported a 3% decline in net product revenue for Q2 2026, driven by ZEJULA and VYVGART, while R&D expenses increased significantly due to licensing fees, though pipeline advancements and a new schizophrenia drug launch offer future potential.

Zai Lab Limited announced its first quarter 2026 financial results, reporting a 6% decrease in total revenues to $99.6 million, primarily driven by lower product sales.

Zai Lab reports a 13% increase in Q3 2025 net product revenue, driven by NUZYRA and XACDURO sales, alongside significant clinical advancements and a reduced net loss.

Zai Lab Limited reported a significant reduction in net loss and increased product revenue for Q2 2025, driven by strong sales of VYVGART and new launches, alongside positive clinical trial advancements.

Zai Lab's Q1 2025 revenue increased by 21% year-over-year, driven by strong sales of NUZYRA, VYVGART, and ZEJULA, while the company continues to advance its pipeline.

Zai Lab's third quarter results show a 47% increase in product revenue compared to the same period last year, driven by strong sales of VYVGART, ZEJULA, and NUZYRA.

Zai Lab's second-quarter revenue surged by 45% year-over-year, fueled by strong sales of VYVGART and continued growth in other key products.

Zai Lab's first quarter 2024 results show a 39% increase in revenue compared to the same period last year, primarily driven by increased sales volume and the launch of new products.